moderna
ValueWalk
Washington (AFP) - Moderna CEO Stephane Bancel told AFP his company's experimental vaccine against melanoma could be available in as little as two years, in what would amount to a landmark step against the most serious form of skin cancer. Globally there were an estimated 325,000 new melanoma cases and 57 ,000 deaths from the disease in 2020. "We think that in some countries the product could be launched under accelerated approval by 2025," he said in an interview. Unlike conventional vaccines, so-called therapeutic vaccines treat rather than prevent a disease. But they also work by training ...
AFP
該公司的ESG策略展示了其推動全球健康和環境永續性的努力,以及對員工和社區的承諾 麻薩諸塞州劍橋, 2023年12月11日 - (亞太商訊) - Moderna公司(納斯達克股票代碼:MRNA)今天將在其第二次環境、社會和治理(ESG)投資者活動上更新其ESG策略。 在2022年11月首次舉辦的ESG日的基礎上,公司將重點介紹今年在ESG道路上取得的進展,並展望未來將進一步影響全球健康和保護環境的工作。 Moderna首席執行官斯特凡·班瑟爾(Stéphane Bancel)表示:「我們的mRNA平台科學造福了全球患者,隨之而來的是巨大的責任,因為單靠科學本身無法解決世界上最大的 健康挑戰。我們致力於超越技術的力量,解決長期存在的健康差距,與社區互動,並認識到人類健康和地球健康密切相連。我們期待在我們已經取得的實質性ESG進展的基礎上,成為Moderna 的最佳版本。” Moderna的ESG策略圍繞著五個面向: 病患藥物:Moderna正在利用其平台開發多種藥物,從疫苗保護數億人免受當前尚無疫苗的常見病毒侵害,到針對幾種罕見疾病的治療,具有巨大的影響機會。 在其臨床試驗中,Moderna相信致力於提供平等醫療可近性的方法是可行且必要的。 公司也致力於利用其平台,迅速應對最大的公共衛生威脅,並推進與爆發響應和大流行病準備相關的優先項目管線。 Moderna長期以來一直將策略合作置於...
ACN Newswire (正體中文)
Washington (AFP) - US biotech company Moderna said Thursday it had mixed results from a large-scale trial of its mRNA flu shot, based on the same technology used in its successful Covid-19 vaccine. Moderna's experimental mRNA-1010 flu shot is "quadrivalent," meaning it targets four strains of flu: A/H1N1, A/H3N2, B/Yamagata and B/Victoria -- selected based on recommendations by the World Health Organization (WHO). The Massachusetts-based company said that its flu shot generated an immune response against influenza A strains that was equal or superior to that of already licensed vaccines. Howev...
AFP
Following is the unofficial transcript of a CNBC interview with Moderna Inc (NASDAQ:MRNA) CEO Stephane Bancel and CNBC “Squawk Box” Co-Anchor Joe Kernen live during the D50X Summit today, Thursday, October 20th. Interview With Moderna CEO Stephane Bancel JOE KERNEN: Hello, thank you. Disruptor of the decade at least, Stephane. And it is a household name. And it’s 50 billion now, but maybe a sore subject – but it shouldn’t be – it was 150 billion at the top. So, congratulations. Q3 2022 hedge fund letters, conferences and more Find A Qualified Financial AdvisorEach advisor has been vetted by Sm...
ValueWalk
Washington (AFP) - Moderna said Friday it is suing rival vaccine makers Pfizer and BioNTech, alleging the partners infringed on its patents in developing their Covid-19 shot administered to hundreds of millions around the world. The lawsuits set up a high-stakes showdown between the leading manufacturers of Covid-19 shots that are a key tool in the fight against the disease. "Moderna believes that Pfizer and BioNTech's Covid-19 vaccine Comirnaty infringes patents Moderna filed between 2010 and 2016 covering Moderna's foundational mRNA technology," the US-based biotech firm said in a statement....
AFP
Washington (AFP) - Moderna on Wednesday said its new Covid booster candidate, which it is hoping to get approved this fall, performed well against Omicron's latest subvariants. The US biotech company announced earlier this month that the so-called "bivalent" vaccine, which targets the original Covid strain and original Omicron BA.1, performed better against both compared to its original Covid vaccine called Spikevax. In new results from a clinical study, the company said that the booster also did well against BA.4 and BA.5, Omicron's latest subvariants that are becoming dominant thanks to thei...
AFP
Washington (AFP) - US biotech company Moderna on Wednesday announced positive results for a new vaccine that targets both the original Covid strain and Omicron, and sees the shot as its "lead candidate" for a booster this fall. The so-called "bivalent" vaccine was tested in a trial of 814 adults and shown to produce 1.75 times more Omicron-specific neutralizing antibodies, which have the power to prevent infection, compared to Moderna's original Spikevax vaccine. All of the participants previously received three doses of Spikevax, and then slightly more than half went on to get a fourth dose o...
AFP
Washington (AFP) - US biotech company Moderna on Wednesday announced positive results for a new vaccine that targets both the original Covid strain and Omicron, and sees the shot as its "lead candidate" for a booster this fall. The so-called "bivalent" vaccine was tested in a trial of 814 adults and shown to produce 1.75 times more Omicron-specific neutralizing antibodies, which have the power to prevent infection, compared to Moderna's original Spikevax vaccine. All of the participants previously received three doses of Spikevax, and then slightly more than half went on to get a fourth dose o...
AFP
Washington (AFP) - US biotech firm Moderna said Thursday it had submitted a request for an emergency use authorization in the United States for its Covid vaccine for children aged six months to under six years. Very young children are the only group that are yet to be eligible for the Covid-19 vaccine in the United States and in most countries, a source of concern for many parents. "We believe (this vaccine) will be able to safely protect these children against SARS-CoV-2, which is so important in our continued fight against Covid-19 and will be especially welcomed by parents and caregivers," ...
AFP
閲覧を続けるには、ノアドット株式会社が「プライバシーポリシー」に定める「アクセスデータ」を取得することを含む「nor.利用規約」に同意する必要があります。
「これは何?」という方はこちら